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Autophagy, a process for recycling cellular constituents, is normally associated with cell survival and is
thought to be beneficial for tumor maintenance. However, in this issue of Cancer Cell, Lamy and colleagues
report that multiple myeloma utilizes caspase-10 to restrain autophagy and undergoes autophagic cell death
upon its removal or inhibition.Autophagy is a stress-induced catabolic
process that is used to capture and
eliminate defective organelles, protein
aggregates, and intracellular microbes
by targeting these to lysosomes for
destruction (reviewed in Choi et al.,
2013). Autophagy can also be deployed
to recycle bulk cytoplasmic constituents
in response to starvation, thereby sustain-
ing cell survival. The role of autophagy in
tumorigenesis has been debated. There
is evidence supporting the view that auto-
phagy is ramped up in transformed cells
and is beneficial for tumor maintenance
and progression (reviewed in White,
2012). On the other hand, there is also
evidence to argue that excessive auto-
phagy can act as a tumor-suppressive
mechanism (Elgendy et al., 2011; Choi
et al., 2013), possibly through initiation of
cell death or senescence. Autophagic
cell death typically displays none of the
features of apoptosis and can be attenu-
ated through ablation of key autophagy
regulators such as Atg proteins or
Beclin-1. There has been skepticism that
cells can die through excessive auto-
phagy (Kroemer and Levine, 2008), how-
ever, a significant body of evidence is
emerging to argue that autophagic cell
death occurs in several important con-
texts (Das et al., 2012). In this issue of
Cancer Cell, Lamy et al. (2013) provide
support for the idea that deregulated
autophagy can result in cellular autodes-
truction in multiple myeloma.
Multiple myeloma is a clonal B cell
malignancy arising from plasma cells,
which are specialized antibody-produc-
ing cells critical for antibody-based immu-
nity. Upon activation by the appropriate
antigen, B cells differentiate into long-
lived plasma cells that are equipped withan extensive endoplasmic reticulum (ER)
and serve as antibody factories, synthe-
sizing prodigious quantities of immuno-
globulin. However, the latter capability is
a source of proteotoxic stress due to
misfolding of a proportion of newly syn-
thesized immunoglobulin, the accumula-
tion of which can lead to ER stress and
cell death if not properly dealt with.
Plasma cells solve this problem by ramp-
ing up several protein handling systems,
including the ubiquitin-proteasome path-
way, the unfolded protein response
(UPR) pathway, and the autophagy
machinery. Autophagy facilitates the
removal of protein aggregates by encap-
sulating these in autophagosomes,
followed by their degradation through
fusion with lysosomes. Indeed, a recent
study has shown that mice deficient in a
critical component of the autophagy
machinery, Atg5, preferentially lose
Atg5-deficient plasma cells and are com-
promised in making long-term antibody
responses as a result (Pengo et al.,
2013). Thus, plasma cells rely heavily on
autophagy, aswell as other protein degra-
dation systems, to keep the factory floor
free of debris that would otherwise choke
up the antibody production line. Because
of this, multiple myeloma displays partic-
ular sensitivity to proteasome inhibitors,
such as bortezomib, and the possibility
of combining such treatments with inhibi-
tors of autophagy is under investigation
(Aronson and Davies, 2012).
Using an RNA interference library
screening approach, Lamy et al. (2013)
searched for molecules critical for the
survival of multiple myeloma cells. Some-
what counter-intuitively, caspase-10, a
protease normally associated with induc-
tion of apoptosis in response to TNFCancer Celfamily members, emerged as a survival
factor for all myeloma cell lines tested
(Lamy et al., 2013). This observation was
confirmed using a variety of approaches.
Further investigation revealed that inhibi-
tion of caspase-10 or knockdown of a
molecule involved in facilitating its activa-
tion, cFLIPL, led to a dramatic increase in
autophagic flux followed by cell death
lacking features of apoptosis. More
compellingly, knockdown of two constitu-
ents of the autophagy machinery, Atg5 or
Beclin-1, led to protection from cell death
caused by caspase-10 inhibition (Lamy
et al., 2013). Taken together, these data
suggest that caspase-10 sets a threshold
for autophagy in multiple myeloma that, if
breached, can lead to autophagic cell
death (Figure 1).
So how does caspase-10 put the
brakes on autophagy? Lamy et al. (2013)
found that BCLAF1, a protein of uncertain
function that was originally identified as a
binding partner of pro-survival Bcl-2
family members, might be the key target
of caspase-10 in this context (Figure 1A).
Although members of the Bcl-2 family
are well known for their role as inhibitors
of apoptosis, several members of this
family also directly interact with and
inhibit Beclin-1, thereby suppressing
autophagy (Elgendy et al., 2011; Choi
et al., 2013). Silencing of BCLAF1 ex-
pression in myeloma abrogated cell
death caused by caspase-10 inhibition,
whereas overexpression of BCLAF1 pro-
moted cell death with features of auto-
phagy. Thus, upon inhibition of caspase-
10, BCLAF1 is stabilized and displaces
Bcl-2 from Beclin-,1 thereby ramping up
autophagy and leading to cell death
(Figure 1B). Several questions remain to
be resolved, however. The precise naturel 23, April 15, 2013 ª2013 Elsevier Inc. 425
Figure 1. Caspase-10 Puts a Brake on Autophagy in Multiple Myeloma
(A) Under steady-state conditions in multiple myeloma, a FLIPL/caspase-10 complex cleaves and inacti-
vates BCLAF1 preventing its participation in autophagy.
(B) Upon inhibition or knockdown of caspase-10, BCLAF1 becomes stabilized, displacing Bcl-2 from
Beclin-1, leading to excessive autophagy followed by autophagic cell death.
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plex remains to be clarified, as does the
issue of whether assembly of this com-
plex is spontaneous or driven by auto-
crine or paracrine death receptor signals.
The role of BCLAF1 as a driver of auto-
phagy and how deregulated autophagy
leads to cell death also require significant
clarification.
Interestingly, previous studies have
also implicated autophagy as a compo-
nent of the cell death response of multiple
myeloma to inhibitors of the protein
handling machinery. Inhibition of auto-
phagy partly antagonized the cytotoxic
effects of bortezomib, suggesting that
autophagic cell death may be partly
responsible for the cytotoxic effects of
proteasome inhibitors in myeloma (Hoang
et al., 2009). Silencing of the UPR sensors
PERK, IRE1, or ATF6 also led to the death
of myeloma cells via excessive induction
of autophagy (Michallet et al., 2011).
Thus, due to the pressures resulting
from the accumulation of misfolded
immunoglobulin, multiple myeloma may426 Cancer Cell 23, April 15, 2013 ª2013 Elsbe uniquely predisposed toward autopha-
gic cell death if protein handling pathways
are tampered with.
One implication of the current study is
that the process leading to the transfor-
mation of plasma cells places their malig-
nant counterparts in a precarious state of
‘‘autophagic stress’’ that needs to be
reined in for such cells to survive. Indeed,
this may be a general property of many
tumors, as several oncogenes such as
H-Ras, B-Raf, and Myc have been found
to ramp up autophagy by different mech-
anisms. Thus, excessive autophagy may
represent a tumor suppressor mechanism
that needs to be counteracted during
tumorigenesis to constrain this tendency
toward self-immolation. Varying solutions
to this problem are likely to be found
among different tumors, with some losing
one allele of the Beclin-1 gene, as is
frequently seen in breast, prostate, and
ovarian tumors, while others upregulate
the expression of Bcl-2 family proteins
that can inhibit the actions of Beclin-1
(Choi et al., 2013). Multiple alternativeevier Inc.strategies may also be employed to
constrain autophagy within acceptable
limits, such as the caspase-10-depen-
dent mechanism described by Lamy
et al. (2013).
Thus, autophagy appears to be a dou-
ble-edged sword that can be beneficial
as well as detrimental to tumor develop-
ment. Tumors need to get the autophagy
balance right to avail its advantages,
which help to cope with the demands of
limited nutrient and oxygen supply, while
avoiding the disadvantages of untram-
melled autophagy, which can lead to
excessive self-consumption of cellular
resources.
An obvious therapeutic implication of
the finding that caspase-10 acts as a
survival factor in multiple myeloma is
that inhibitors of caspase-10 might have
therapeutic utility in this malignancy.
However, such inhibitors would have to
be sufficiently specific to avoid disruption
of caspases in critical processes such as
apoptosis and inflammation. One of the
key lessons from the current study is
that, in cancer, too much autophagy
may be as bad as too little. Thus, encour-
aging the self-cannibalistic tendencies of
multiple myeloma may be a viable thera-
peutic strategy.
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